Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prostate cancer

Draft USPSTF 2017 recommendation on PSA testing — a sea-change?

Increased evidence that prostate-cancer-specific mortality can be reduced using serum PSA screening, in addition to the increasing role of active surveillance in reducing overtreatment underlies the revised USPSTF recommendation, which now supports selective use of PSA testing. However, this recommendation should not be interpreted as a license to return to the unthinking use of PSA testing of men between 50 to 70 years of age.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Bibbins-Domingo, K., Grossman, D. C. & Curry, S. J. The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA 317, 1949–1950 (2017).

    Article  Google Scholar 

  2. 2

    Carlsson, S. et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J. Clin. Oncol. 30, 2581–2584 (2012).

    Article  Google Scholar 

  3. 3

    Drazer, M. W. et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 15, 1491–1498 (2014).

    Article  Google Scholar 

  4. 4

    Fleshner, K., Carlsson, S. V. & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26–37 (2017).

    CAS  Article  Google Scholar 

  5. 5

    Eapen, R. S., Herlemann, A., Washington, S. L. III & Cooperberg, M. R. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Curr. Opin. Urol. 27, 205–209 (2017).

    Article  Google Scholar 

  6. 6

    Moyer, V. A. & U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 10–134 (2012).

    Google Scholar 

  7. 7

    Schröder, F. H. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027–2035 (2014).

    Article  Google Scholar 

  8. 8

    Buzzoni, C. et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer. Eur. Urol. 68, 885–890 (2015).

    Article  Google Scholar 

  9. 9

    Murphy, D. G. & Loeb, S. Prostate cancer: growth of AS in the USA signals reduction in overtreatment. Nat. Rev. Urol. 12, 604–605 (2015).

    Article  Google Scholar 

  10. 10

    Bokhorst, L. P. et al. A decade of active surveillance in the PRIAS Study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur. Urol. 70, 954–960 (2016).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Theodorus H. Van der Kwast.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Van der Kwast, T., Roobol, M. Draft USPSTF 2017 recommendation on PSA testing — a sea-change?. Nat Rev Urol 14, 457–458 (2017).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing